Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.


Christie Administration Announces CDC Grant Funding Totaling More than $7.6 Million to Combat Opioid Epidemic

Opioid Abuse 1Trenton, NJ, September 5, 2016New Jersey Business reports that Governor Chris Christie on September 1 announced that the Centers for Disease Control and Prevention (CDC) had awarded the New Jersey Department of Health (DOH) a $727,688 competitive grant to enhance efforts to curb the opioid crisis through a series of initiatives and the New Jersey Department of Human Services (DHS) approximately $6.9 million to target prescription and opioid misuse.

“Today is International Overdose Awareness Day, a reminder that the disease of addiction is preventable through education and intervention,” said Governor Christie.  “These funding grants are another important step in combating opioid misuse and abuse in New Jersey while strengthening our ability to positively impact the opioid crisis in our state by saving lives.” Continue reading

President Obama Signs Bill to Address Opioid Addition Despite Its Shortcomings

Opioid Abuse 2Washington, DC, July 25, 2016 The Hill reports that President Obama signed a bill aimed at addressing opioid addiction Friday, though he called out Republicans for the measure’s shortcomings.

Lawmakers in both parties reached a compromise over the bipartisan Comprehensive Addiction and Recovery Act, though Senate Democrats held out hope until the final hour that they could win more funding for treatment.

“This legislation includes some modest steps to address the opioid epidemic,” Obama said in a statement.  “Given the scope of this crisis, some action is better than none. However, I am deeply disappointed that Republicans failed to provide any real resources for those seeking addiction treatment to get the care that they need.” Continue reading

FDA Announces Enhanced Warnings for Immediate-Release Opioid Pain Medications

FDA blueWashington, DC, March 23, 2016 ― The U.S. Food and Drug Administration (FDA), in a continuing effort to educate prescribers and patients about the potential risks related to opioid use, yesterday announced required class-wide safety labeling changes for immediate-release (IR) opioid pain medications.

Among the changes, the FDA is requiring a new boxed warning about the serious risks of misuse, abuse, addiction, overdose and death.

Yesterday’s actions are among a number of steps the agency recently outlined in a plan to reassess its approach to opioid medications.  The plan is focused on policies aimed at reversing the epidemic, while still providing patients in pain access to effective relief. Continue reading

FDA Top Officials Call for Sweeping Review FDA Opioids Policies

FDA blueWashington, DC, February 7, 2016 ― In response to the opioid abuse epidemic, Dr. Robert Califf, the Food and Drug Administration’s (FDA) Deputy Commissioner for Medical Products and Tobacco, along with other FDA leaders, called for a far-reaching action plan to reassess the agency’s approach to opioid medications.

The plan, announced on February 4, will focus on policies aimed at reversing the epidemic, while still providing patients in pain access to effective relief.

The FDA will: Continue reading